Clinical Trial Update: Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating ravulizumab for thrombotic microangiopathy associated with a trigger was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Microangiopathy

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Thrombotic Microangiopathy | Phase 3 | Status: TERMINATED | Results posted: 2023-12-12